Saqib Islam

New Capabilities

As of September 2026: Leading the company through the Phase 2 to Phase 3 transition

Beeline Medicines' afimetoran, a once-daily oral pill for lupus, met its primary endpoint in a Phase 2 trial. The result moves the biotech into Phase 3 (pivotal) development for two forms of the disease.

Updated Sep 9